‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.

Finding that Amgen Inc. has suffered irreparable harm from Sanofi and Regeneron Pharmaceuticals Inc.’s marketing of their PCSK9 inhibitor Praluent (alirocumab), a competitor to Amgen’s Repatha (evolocumab), and that monetary damages are inadequate, a district court judge issued a permanent injunction to block US sales of Praluent.

However, in her Jan. 5 order, Delaware District Judge Sue Robinson delayed imposition of the injunction for 30...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.